See more : Vibe Growth Corporation (VIBEF) Income Statement Analysis – Financial Results
Complete financial analysis of Nevro Corp. (NVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nevro Corp., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Corby Spirit and Wine Limited (CSW-B.TO) Income Statement Analysis – Financial Results
- DMC Mining Limited (DMM.AX) Income Statement Analysis – Financial Results
- Togami Electric Mfg. Co., Ltd. (6643.T) Income Statement Analysis – Financial Results
- Daiken Co.,Ltd. (5900.T) Income Statement Analysis – Financial Results
- AM Resources Corp. (AMRCF) Income Statement Analysis – Financial Results
Nevro Corp. (NVRO)
About Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 425.17M | 406.37M | 386.91M | 362.05M | 390.26M | 387.29M | 326.67M | 228.50M | 69.61M | 32.57M | 23.50M | 18.15M |
| Cost of Revenue | 135.11M | 130.00M | 120.86M | 112.15M | 121.91M | 113.97M | 98.98M | 75.43M | 28.12M | 11.28M | 9.47M | 7.53M |
| Gross Profit | 290.06M | 276.37M | 266.04M | 249.90M | 268.35M | 273.32M | 227.69M | 153.07M | 41.49M | 21.30M | 14.03M | 10.62M |
| Gross Profit Ratio | 68.22% | 68.01% | 68.76% | 69.02% | 68.76% | 70.57% | 69.70% | 66.99% | 59.60% | 65.38% | 59.69% | 58.53% |
| Research & Development | 54.42M | 53.07M | 47.67M | 45.60M | 59.02M | 48.46M | 37.56M | 33.73M | 21.38M | 19.82M | 20.35M | 15.66M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 334.70M | 322.14M | 309.31M | 267.15M | 305.81M | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 18.83M | 14.09M |
| Other Expenses | 246.00K | 511.00K | -814.00K | -495.00K | -697.00K | -1.16M | 1.07M | -1.10M | -1.74M | -1.88M | -654.00K | 186.00K |
| Operating Expenses | 389.37M | 375.20M | 356.98M | 312.75M | 364.83M | 315.07M | 257.27M | 176.15M | 103.85M | 49.60M | 39.18M | 29.75M |
| Cost & Expenses | 524.48M | 505.20M | 477.84M | 424.90M | 486.73M | 429.03M | 356.25M | 251.59M | 131.97M | 60.88M | 48.65M | 37.28M |
| Interest Income | 14.17M | 4.02M | 671.00K | 2.96M | 6.02M | 4.87M | 3.16M | 1.69M | 575.00K | 0.00 | 153.00K | 139.00K |
| Interest Expense | 8.01M | 6.43M | 19.75M | 21.81M | 10.93M | 10.40M | 9.90M | 6.39M | 2.73M | 16.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.54M | 10.33M | 8.68M | 8.19M | 7.80M | 3.89M | 2.51M | 1.72M | 614.00K | 96.00K | 47.00K | 39.00K |
| EBITDA | -78.31M | 21.02M | -102.40M | -52.21M | -83.36M | -37.86M | -22.84M | -22.04M | -62.92M | -30.09M | -25.10M | -19.09M |
| EBITDA Ratio | -18.42% | -50.16% | -18.33% | -17.36% | -24.72% | -10.78% | -9.05% | -9.55% | -89.60% | -86.90% | -106.83% | -105.18% |
| Operating Income | -99.31M | -98.84M | -90.93M | -62.85M | -96.48M | -41.74M | -29.58M | -23.08M | -62.37M | -28.31M | -25.15M | -19.13M |
| Operating Income Ratio | -23.36% | -24.32% | -23.50% | -17.36% | -24.72% | -10.78% | -9.05% | -10.10% | -89.60% | -86.90% | -107.03% | -105.40% |
| Total Other Income/Expenses | 1.45M | -1.90M | -19.89M | -19.35M | -5.61M | -6.69M | -5.67M | -7.07M | -3.90M | -1.90M | -501.00K | 325.00K |
| Income Before Tax | -97.86M | 4.26M | -130.83M | -82.20M | -102.09M | -48.44M | -35.25M | -30.16M | -66.27M | -30.20M | -25.65M | -18.81M |
| Income Before Tax Ratio | -23.02% | 1.05% | -33.81% | -22.70% | -26.16% | -12.51% | -10.79% | -13.20% | -95.20% | -92.72% | -109.16% | -103.61% |
| Income Tax Expense | -5.65M | 1.26M | 534.00K | 868.00K | 1.60M | 768.00K | 1.41M | 1.62M | 1.17M | 478.00K | 362.00K | 162.00K |
| Net Income | -92.21M | 3.00M | -131.36M | -83.07M | -103.69M | -49.21M | -36.66M | -31.78M | -67.43M | -30.68M | -26.01M | -18.97M |
| Net Income Ratio | -21.69% | 0.74% | -33.95% | -22.94% | -26.57% | -12.70% | -11.22% | -13.91% | -96.88% | -94.19% | -110.70% | -104.50% |
| EPS | -2.56 | 0.09 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| EPS Diluted | -2.56 | 0.08 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| Weighted Avg Shares Out | 35.98M | 35.32M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
| Weighted Avg Shares Out (Dil) | 35.98M | 35.53M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
Abstract Presentations Highlight Durable Pain Relief and Improved Quality of Life for Patients Receiving 10 kHz Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy and Non-Surgical Back Pain Symposium on the Future of SCS and How AI Technology Can Improve...
Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
Wednesday, August 9, 2023 at 8:30 am Eastern Time REDWOOD CITY, Calif. , July 12, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin...
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued
Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts could bring significant FCF growth and stock price appreciation.
Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript
Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.98 per share a year ago.
How Much Upside is Left in Nevro (NVRO)? Wall Street Analysts Think 53.7%
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Why Nevro Stock Is Tanking Today
Today Nevro announced the appointment of a new CEO/president along with its preliminary 2023 Q1 financial results. With a possible recession looming, investors are exiting the cash-flow-negative medtech today.
Nevro Names Kevin Thornal as New Chief Executive Officer and President
D. Keith Grossman to be Appointed as Executive Chairman Company Announces Preliminary, Unaudited Worldwide Revenue for First Quarter of 2023 of $96.3 Million and Reaffirms Full-Year 2023 Revenue and Non-GAAP Adjusted EBITDA Guidance REDWOOD CITY, Calif., April 19, 2023 /PRNewswire/...
Source: https://incomestatements.info
Category: Stock Reports